"同仁堂科技"（01666.HK）"安宫牛黄丸"产能提升项目中的关键节点——新增生产线，已经通过药监部 门GMP认证。这标志着生产现场、设备设施等软、硬件准备已全部就绪。在拿到药监部门的证书后， 新线即可投入生产。届时，产能预计将实现30%以上的提升。 安宫牛黄丸是同仁堂的明星产品。近年来，市场对安宫牛黄丸的关注度不断提高，需求也随之增高。观 研报告网发布的《中国安宫牛黄丸行业发展现状分析与未来前景预测报告（2023—2030年）》显示，在 这一细分市场，同仁堂目前占据的市场份额约50%。 新增的生产线，对生产面积进行了扩容，在生产布局上进行了优化调整，实现了从合坨工序到外包工序 均位于同一楼层，有效缩短了各工序之间的距离，从而提高了整体生产效率。企业还引入了全新的智能 为进一步满足市场需求，同仁堂科技加速推动产能提升。企业相关负责人表示，此前存量的安宫牛黄丸 生产线需要在"天然方"（天然牛黄、天然麝香）安宫牛黄丸和"体培方"安宫牛黄丸（体外培育牛黄、人 工麝香）两个品类之间进行切换。在新增生产线后，产线分工将更为明确，一条产线只负责一个品类的 生产，减少了不同品类"切换"生产带来工作量，"专一提升效率，更可 ...

Group 1 - The core viewpoint of the news is that Tongrentang Technology has made significant progress in its traditional Chinese medicine processing project in Yutian, Hebei, with over 50 sets of equipment successfully installed and operational work underway [1][2][3] Group 2 - In 2024, coinciding with the 10th anniversary of the Beijing-Tianjin-Hebei coordinated development strategy, Tongrentang Technology has initiated the construction of a traditional Chinese medicine processing workshop to enhance its processing capacity and optimize its industrial layout [2] - The project is located in the National Agricultural Science and Technology Park in Yutian County, Tangshan City, covering an area of 80 acres, primarily focusing on the preparation of raw medicinal materials [2] - The first phase of the project includes three main buildings: Factory 1, Pre-treatment Workshop 2, and Raw Material Storage 3, along with eight auxiliary buildings [2] Group 3 - Since the project's launch, multiple construction milestones have been successfully achieved, with all three main buildings completed and finishing touches on decoration and renovation underway [3] - The successful installation of production equipment marks a critical milestone, bringing the project closer to completion and production [3] - Once phase one is completed, the production base will have the capacity to produce 4 million kilograms of processed medicinal materials annually, enhancing the company's processing capabilities and supply capacity [3]

Core Viewpoint - Tongrentang Technology reported a revenue of 7.26 billion and a net profit of 0.887 billion for the fiscal year 2024, demonstrating resilience in a challenging pharmaceutical market environment [1] Group 1: Financial Performance - The company achieved a revenue of 7.26 billion and a net profit of 0.887 billion during the reporting period [1] - Despite challenges such as rising raw material prices and decreased foot traffic in stores, the company improved its overall operational quality [1] Group 2: Innovation and R&D - Tongrentang Technology increased its investment in research and development, accelerating the development of innovative drugs and classic formulas [2] - The company received clinical trial approval for Qishen Granules, marking its first clinical approval for a traditional Chinese medicine in eight years [2] - Several products underwent pharmacological mechanism studies, enhancing their market competitiveness and clinical recognition [2] Group 3: Market Strategy and Product Expansion - In response to external challenges, the company adjusted its market strategy, focusing on channel management, price stability, and terminal empowerment [3] - The company launched promotional activities for its "Yuyao 300" product line, resulting in nine products exceeding 0.1 billion in sales [3] Group 4: Channel Development - Tongrentang Technology strengthened its partnerships with major distributors and conducted over 450 promotional events in previously untapped markets [4] - The company aimed to enhance product distribution rates and terminal effectiveness through targeted market strategies [4] Group 5: Risk Management and Future Plans - The company plans to enhance its governance and core competitiveness to address risks and challenges [5] - Future initiatives include a new round of collaborative innovation in traditional Chinese medicine, aiming to complete clinical research on five products by 2025 [5]

Core Viewpoint - The Chinese medicine industry is poised for high-quality development driven by government policies, with Tong Ren Tang Technology (01666.HK) positioned to benefit from this trend through its comprehensive capabilities and strategic alignment with policy directions [1][5]. Financial Performance - In 2024, Tong Ren Tang Technology achieved revenue of 7.26 billion RMB, a year-on-year increase of 7.18%, and a net profit of 888 million RMB, with a return to shareholders of 0.18 RMB per share [2]. - Despite facing cost pressures, the company maintained stable revenue performance, leveraging its full industry chain advantages and refined management to control procurement costs [2][3]. - The company reported 56 products with sales exceeding 5 million RMB, including 9 products with sales over 100 million RMB, indicating robust growth in core products [3]. Market Opportunities - The government’s support for traditional Chinese medicine and consumption policies creates favorable conditions for market expansion of core products like An Gong Niu Huang Wan and Gan Mao Qing Re Granules [6]. - The adjustment of the medical insurance catalog in 2024 is expected to favor innovative Chinese medicine products, potentially leading to revenue recovery for the company [6]. Competitive Strengths - Tong Ren Tang Technology's competitive edge lies in its full industry chain, covering everything from raw material cultivation to terminal services, ensuring stable supply and quality [7]. - The company is actively promoting product innovation and has received approval for its innovative drug Qi Shen Granules, which is set to enter clinical trials [8]. - The company has been recognized for its research achievements, winning the 2024 Beijing Science and Technology Progress Award, showcasing its strong R&D capabilities [8]. Cost Dynamics - The company has faced pressure from rising raw material costs, but a recent decline in Chinese medicinal material prices is expected to improve profitability [10]. - The overall cost pressure on downstream Chinese medicine companies is anticipated to decrease, allowing for improved margins [10]. Long-term Growth Potential - The company is positioned for value growth through policy-driven short-term performance recovery, industry chain advantages, and international market expansion [11]. - With a dynamic P/E ratio of approximately 9 times, the company is expected to maintain a valuation premium due to its brand value and market competitiveness [11].

免責聲明 | 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因 公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 | | | --- | --- | | 股票發行人現金股息公告 | | | 發行人名稱 | 北京同仁堂科技發展股份有限公司 | | 股份代號 | 01666 | | 多櫃檯股份代號及貨幣 | 不適用 | | 相關股份代號及名稱 | 不適用 | | 公告標題 | 截至二零二四年十二月三十一日止年度之末期股息 | | 公告日期 | 2025年3月28日 | | 公告狀態 | 新公告 | | 股息信息 | | | 股息類型 | 末期 | | 股息性質 | 普通股息 | | 財政年末 | 2024年12月31日 | | 宣派股息的報告期末 | 2024年12月31日 | | 宣派股息 | 每 股 0.18 RMB | | 股東批准日期 | 有待公佈 | | 香港過戶登記處相關信息 | | | 派息金額及公司預設派發貨幣 | 有待公佈 | | 匯率 | 有待公佈 | | 除淨日 | 有待公佈 | | 為 ...

Financial Performance - For the fiscal year ending December 31, 2024, the company's revenue was RMB 7,259.644 million, an increase of 7.18% from RMB 6,773.463 million in the previous year[4] - The net profit for the same period was RMB 886.933 million, a decrease of 10.62% compared to RMB 992.313 million in the previous year[4] - Earnings attributable to the company's owners were RMB 521.795 million, down 11.59% from RMB 590.188 million in the previous year[4] - The basic and diluted earnings per share were RMB 0.41, compared to RMB 0.46 in the previous year[4] - The total comprehensive income for the year was RMB 953.635 million, compared to RMB 1,041.687 million in the previous year[13] - Financial income for 2024 was RMB 76,874, down 19.4% from RMB 95,351 in 2023[34] - The net financial income decreased significantly to RMB 8,577 in 2024 from RMB 46,049 in 2023[34] - The total income tax expense for 2024 is RMB 174,278,000, compared to RMB 170,142,000 in 2023, reflecting an increase of approximately 0.8%[41] - The effective tax rate for 2024 is 21.2%, up from 20.0% in 2023, indicating a rise in the tax burden on pre-tax profits[43] - Basic earnings per share for 2024 is RMB 0.41, down from RMB 0.46 in 2023, representing a decrease of approximately 10.9%[51] - The profit attributable to the owners of the company for 2024 is RMB 521,795,000, compared to RMB 590,188,000 in 2023, showing a decline of about 11.6%[51] Assets and Liabilities - Total assets increased to RMB 14,408,591 thousand in 2024, up from RMB 13,507,742 thousand in 2023, representing a growth of 6.6%[15] - Current assets rose to RMB 10,833,476 thousand in 2024, compared to RMB 10,058,898 thousand in 2023, marking an increase of 7.7%[15] - Total equity rose to RMB 10,165,079 thousand in 2024, up from RMB 9,651,885 thousand in 2023, which is an increase of 5.3%[16] - Non-current liabilities decreased to RMB 1,402,041 thousand in 2024 from RMB 1,616,972 thousand in 2023, a decline of 13.2%[16] - Current liabilities increased to RMB 2,841,471 thousand in 2024, compared to RMB 2,238,885 thousand in 2023, representing an increase of 27%[16] - The company's reserves increased to RMB 5,925,413 thousand in 2024, up from RMB 5,608,633 thousand in 2023, reflecting a growth of 5.6%[16] - The total assets of the company as of December 31, 2024, amount to RMB 14,408,591,000, while total liabilities are RMB 4,243,512,000[55] Inventory and Receivables - Inventory increased significantly to RMB 5,165,995 thousand in 2024, up from RMB 4,744,433 thousand in 2023, reflecting a growth of 8.9%[15] - The company reported a significant increase in accounts receivable to RMB 1,103,565 thousand in 2024, compared to RMB 888,333 thousand in 2023, which is an increase of 24.2%[15] - Accounts receivable increased to RMB 887,968,000 in 2024 from RMB 721,230,000 in 2023, with third-party receivables rising to RMB 612,158,000[63] - The net value of accounts receivable and notes was RMB 1,103,565,000 in 2024, compared to RMB 888,333,000 in 2023[63] Strategic Initiatives - The company plans to enhance its marketing strategies and optimize its strategic management system to improve market influence and share[8] - The company is focusing on technological innovation and industry upgrades to drive modernization in the traditional Chinese medicine sector[8] - The company aims to strengthen its product offerings and expand sales channels to enhance competitiveness in a challenging market environment[6] - The company is focusing on the development of classic formulas, including Linggui Zhugan Decoction and Shaoyao Gancao Decoction[89] - The company is conducting clinical research on existing products to enhance their market competitiveness and clinical acceptance[89] Research and Development - Research and development expenses for 2024 were RMB 84,823, a decrease of 27.8% from RMB 117,556 in 2023[37] - Research and development expenditure (excluding employee benefits, depreciation, and amortization) was RMB 84.8 million, accounting for 1.17% of revenue[104] Market Performance - In 2024, the sales revenue of traditional Chinese medicine products reached RMB 5,897,495, an increase of 7.3% from RMB 5,495,458 in 2023[28] - The sales of the Liuwei Dihuang Wan series increased by 10.71%, while the Shengmai Drink series saw a growth of 14.85% year-on-year[89] - Tong Ren Tang Guo Yao achieved a sales revenue of RMB 1,473.4 million in 2024, representing a year-on-year growth of 7.04%[91] - The six subsidiaries focused on traditional Chinese medicine raw materials achieved a combined sales revenue of RMB 482.9 million, with a year-on-year growth of 13.76%[92] Corporate Governance - The group is committed to adhering to corporate governance standards as per the Hong Kong Stock Exchange listing rules, ensuring a robust governance framework[117] - Ernst & Young has been appointed as the auditor for the fiscal year ending December 31, 2024, and their work aligns with the group's financial performance announcements[123] Challenges and Outlook - The company faced significant challenges due to rising raw material costs, impacting production costs and supply chain management[86] - The group aims to optimize production processes and enhance production efficiency while controlling costs and inventory levels, focusing on "maintaining output value, controlling costs, adjusting structure, and reducing inventory"[114] - The group anticipates a prosperous and internationally influential traditional Chinese medicine industry, supported by national health strategies and policies[114]

Core Viewpoint - Beijing Tongrentang Technology Development Co., Ltd. has launched the "Cultivated Organic Version" of the An Gong Niu Huang Wan to meet the market demand for cardiovascular emergency medications, leveraging traditional medicine and research innovation [1][4]. Product Overview - An Gong Niu Huang Wan is a well-known product of Tongrentang, used for clearing heat and detoxifying, with applications in high fever, stroke, and other severe conditions [2]. - The product is categorized into "Natural Formula" and "Cultivated Formula," with the latter using lab-cultivated ingredients that closely match the efficacy of natural components [2][3]. Research and Development - The lab-cultivated cow bile (Niu Huang) has been shown to have similar composition and stability to natural cow bile, with studies indicating no significant difference in efficacy and safety between the two formulations for treating stroke [2][3]. - The development of artificial musk, which shares similar pharmacological effects with natural musk, has been a collaborative effort over two decades, enhancing the product's therapeutic profile [3]. Quality and Standards - The "Cultivated Organic Version" of An Gong Niu Huang Wan utilizes selected organic herbs that meet national organic standards, ensuring no chemical pesticides or fertilizers are used in the production process [3]. - The production process adheres to the national pharmacopoeia standards, reflecting a commitment to high-quality manufacturing [3]. Market Strategy - The introduction of the "Cultivated Organic Version" is a strategic move to segment the market for cardiovascular traditional Chinese medicine, enhancing product competitiveness and catering to diverse consumer needs [4]. - This product diversification aims to tap into a broader consumer base and drive sales potential across the supply chain [4].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公佈全部或任何部份內容 而產生或因依賴該等內容而引致之任何損失承擔任何責任。 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1666） 自願公告 獲發中成藥註冊證明書 本公告由北京同仁堂科技發展股份有限公司（「本公司」，連同本公司之附屬公司，「本 集團」）之董事會（「董事會」）自願作出，旨在使本公司股東及潛在投資者了解本集 團之最新業務發展。 董事會欣然宣佈，本公司之附屬公司北京同仁堂國藥有限公司（「同仁堂國藥」）於近 日收到香港中醫藥管理委員會頒發的《中成藥註冊證明書》，准許將「金釵石斛散【同 仁堂】」在中華人民共和國香港特別行政區（「香港」）出售，相關情況公告如下： 一、 藥品基本狀況 藥品名稱：金釵石斛散【同仁堂】 註冊持有人及地址：北京同仁堂國藥有限公司，香港新界大埔工業邨大景街 3 號 註冊編號：HKC-18754 證明書有效期限：至 2030 年 1 月 23 日止 1 二、 藥品的其他相關情況 「金釵石斛散【同仁堂】」功能主治為用於熱病津傷，口感煩渴，胃陰 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本通告之內容概不負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不就因本通告全部 或任何部份內容而產生或因依賴該等內容而引致之任何損失承擔任何責任。 邸淑兵 董事長 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1666） 董事會會議通告 北京同仁堂科技發展股份有限公司(「本公司」)之董事(「董事」)會(「董事會」) 謹此宣佈，董事會會議將於二零二五年三月二十八日(星期五)假座中華人民共和 國北京市豐台區南三環中路二十號舉行，以便進行以下事項： 承董事會命 北京同仁堂科技發展股份有限公司 中國，北京 二零二五年三月十三日 截至本公告日期，董事會包括執行董事邸淑兵先生、陳加富先生及馮智梅女士， 非執行董事張毅先生、王春蕊女士及馮莉女士，獨立非執行董事陳清霞女士、詹 原競先生及李兆彬先生。 1 （1） 考慮及批准本公司及其附屬公司(「本集團」)截至二零二四年十二月三十 一日止年度之經審核綜合業績，以及本公司擬於香港聯合交易所有限公司 網站刊登之本集團經審核綜合業績之公告； （2） 考慮建議派發末期股息(如有)； （3） 考慮暫停辦理本公司股份過 ...

定價政策 誠如該公告所披露，根據新商標許可協議，許可費相等於本公司每年許可費基數之0.3%。 釐定年度上限的基準時，本公司已參考（其中包括）其他許可方對於類似字號和商標授 權交易收取的許可費。為確保新商標許可協議項下許可費屬公平合理且按一般商業條款 進行，本公司已對上市公司及其控股股東或其他關連人士之間類似字號和商標授權交易 進行市場調查。根據所取得的近20份結果顯示，就類似交易支付予許可方的許可費介乎 0.12%至1.5%。經考慮市場調查及「同仁堂」品牌的市場價值和認可度的顯著增長，本公 司相信新商標許可協議項下的許可費符合當前市場慣例及標準。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 （於中華人民共和國註冊成立的股份有限公司） （股份代號： 1666 ） 補充公告 續訂持續性關連交易 新商標許可協議 茲提述北京同仁堂科技發展股份有限公司（「本公司」）日期為二零二四年十二月三十 日之公告（「該公告」），內容有關續訂新商標許可協議項下擬進行之持 ...